Cormedix Stock Performance
| CRMD Stock | USD 9.96 0.37 3.58% |
On a scale of 0 to 100, CorMedix holds a performance score of 14. The firm shows a Beta (market volatility) of 1.28, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CorMedix will likely underperform. Please check CorMedix's sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to make a quick decision on whether CorMedix's price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in CorMedix are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain primary indicators, CorMedix exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.31 | Five Day Return (7.95) | Year To Date Return 170.29 | Ten Year Return 40.55 | All Time Return (32.07) |
Last Split Factor 1:5 | Dividend Date 2019-03-26 | Last Split Date 2019-03-26 |
1 | CorMedix announces new commercial agreement | 09/09/2024 |
2 | Acquisition by Zelnick Kaufman Beth of 200000 shares of CorMedix at 3.3 subject to Rule 16b-3 | 10/11/2024 |
3 | CorMedix Inc. A Bull Case Theory | 10/22/2024 |
4 | CorMedix Q3 2024 Earnings Preview | 10/29/2024 |
5 | CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update | 10/30/2024 |
6 | CorMedix Q3 2024 Earnings Call Transcript | 10/31/2024 |
7 | Wall Street Analysts See a 52.15 percent Upside in CorMedix Can the Stock Really Move This High | 11/04/2024 |
8 | CorMedix Upgraded to Strong Buy What Does It Mean for the Stock | 11/08/2024 |
9 | Heres Why CorMedix Inc.s CEO Compensation Is The Least Of Shareholders Concerns | 11/14/2024 |
10 | Cormedix EVP Elizabeth Hurlburt sells 1.57m in stock | 11/19/2024 |
| Begin Period Cash Flow | 43.4 M |
CorMedix |
CorMedix Relative Risk vs. Return Landscape
If you would invest 617.00 in CorMedix on August 27, 2024 and sell it today you would earn a total of 379.00 from holding CorMedix or generate 61.43% return on investment over 90 days. CorMedix is currently generating 0.8713% in daily expected returns and assumes 4.8223% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than CorMedix, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CorMedix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CorMedix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CorMedix, and traders can use it to determine the average amount a CorMedix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1807
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.82 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.87 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average CorMedix is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CorMedix by adding it to a well-diversified portfolio.
CorMedix Fundamentals Growth
CorMedix Stock prices reflect investors' perceptions of the future prospects and financial health of CorMedix, and CorMedix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CorMedix Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 558.87 M | ||||
| Shares Outstanding | 60.68 M | ||||
| Price To Earning | (0.88) X | ||||
| Price To Book | 10.29 X | ||||
| Price To Sales | 49.29 X | ||||
| Gross Profit | 61.67 K | ||||
| EBITDA | (48.89 M) | ||||
| Net Income | (46.34 M) | ||||
| Cash And Equivalents | 64.62 M | ||||
| Cash Per Share | 1.57 X | ||||
| Total Debt | 667.63 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (38.41 M) | ||||
| Earnings Per Share | (0.80) X | ||||
| Market Capitalization | 604.34 M | ||||
| Total Asset | 82.06 M | ||||
| Retained Earnings | (321.7 M) | ||||
| Working Capital | 68.05 M | ||||
| Current Asset | 37.06 M | ||||
| Current Liabilities | 3.06 M | ||||
About CorMedix Performance
By analyzing CorMedix's fundamental ratios, stakeholders can gain valuable insights into CorMedix's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CorMedix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CorMedix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.4 K | 3.5 K | |
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.56) | (0.59) | |
| Return On Equity | (0.66) | (0.63) |
Things to note about CorMedix performance evaluation
Checking the ongoing alerts about CorMedix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CorMedix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CorMedix appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (46.34 M) with profit before overhead, payroll, taxes, and interest of 61.67 K. | |
| CorMedix currently holds about 64.62 M in cash with (38.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| CorMedix has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Cormedix EVP Elizabeth Hurlburt sells 1.57m in stock |
- Analyzing CorMedix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CorMedix's stock is overvalued or undervalued compared to its peers.
- Examining CorMedix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CorMedix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CorMedix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CorMedix's stock. These opinions can provide insight into CorMedix's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CorMedix Stock analysis
When running CorMedix's price analysis, check to measure CorMedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CorMedix is operating at the current time. Most of CorMedix's value examination focuses on studying past and present price action to predict the probability of CorMedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CorMedix's price. Additionally, you may evaluate how the addition of CorMedix to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |